Acurx Pharmaceuticals (ACXP)
NASDAQ:ACXP
Want to see ACXP full AI Analyst Report?
ACXP Stock Chart & Stats
$2.78
-$0.07(-8.37%)
At close: 4:00 PM EST
$2.78
-$0.07(-8.37%)
Day’s Range― - ―
52-Week Range$1.33 - $21.02
Previous CloseN/A
Volume243.54K
Average Volume (3M)1.14M
Market Cap
$7.09M
Enterprise Value-$6.12M
Total Cash (Recent Filing)$9.25M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.31
Next Earnings
Aug 17, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.91
Shares Outstanding4,297,738
10 Day Avg. Volume3,231,033
30 Day Avg. Volume1,135,368
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.71
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-0.86
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.82
Forecast
1Y Price Target
$17.00Price Target Upside511.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.16
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Phase II Efficacy And Low RecurrenceRobust Phase II results with very high cure rates and no observed short-term recurrences materially strengthen the development program's probability of success. Durable clinical signal reduces reliance on surrogate endpoints and supports a registrational package, aiding regulatory discussions and partner interest over the next 2–6 months.
Favorable FDA Guidance And LPAD OptionA structural regulatory shift to a single pivotal-trial plus confirmatory evidence pathway and LPAD eligibility materially lowers the evidentiary and cost burden for registration. This can shorten timelines, reduce trial size/cost, and improves strategic flexibility for trial design and potential accelerated approval over the next several months.
Debt-free Balance SheetZero debt preserves financial flexibility and reduces insolvency risk during capital raises. For a pre-revenue biotech, lack of leverage limits fixed obligations, enabling management to prioritize development and structure funding (equity or partnerships) without near-term debt service constraints over the medium term.
Bears Say
Modest Cash Relative To Phase III NeedsWith only modest cash on hand versus the funding scale required for pivotal trials, the company faces near-term financing imperatives. This creates execution risk: potential delays, scaled-back programs, or dilutive financings that can affect timelines and ability to run robust registrational studies over the next 2–6 months.
Pre-revenue Business With Ongoing Cash BurnNo product revenue and continuing negative operating cash flow mean the company must rely on external capital or partnerships. This structural funding dependency raises dilution and continuity risk, constraining investment choices and increasing sensitivity to market financing conditions in the medium term.
Small, Open-label RCDI Pilot And Design UncertaintyA tiny, non-randomized 20-patient pilot provides limited confirmatory evidence for regulators and payers. Remaining uncertainties around comparator choice, endpoints and follow-up mean larger controlled trials will likely be required, increasing cost and timeline risk despite favorable guidance.
Acurx Pharmaceuticals News
ACXP FAQ
What was Acurx Pharmaceuticals’s price range in the past 12 months?
Acurx Pharmaceuticals lowest stock price was $1.32 and its highest was $21.02 in the past 12 months.
What is Acurx Pharmaceuticals’s market cap?
Acurx Pharmaceuticals’s market cap is $7.09M.
When is Acurx Pharmaceuticals’s upcoming earnings report date?
Acurx Pharmaceuticals’s upcoming earnings report date is Aug 17, 2026 which is in 64 days.
How were Acurx Pharmaceuticals’s earnings last quarter?
Acurx Pharmaceuticals released its earnings results on May 12, 2026. The company reported -$0.62 earnings per share for the quarter, beating the consensus estimate of -$1.2 by $0.58.
Is Acurx Pharmaceuticals overvalued?
According to Wall Street analysts Acurx Pharmaceuticals’s price is currently Undervalued.
Does Acurx Pharmaceuticals pay dividends?
Acurx Pharmaceuticals does not currently pay dividends.
What is Acurx Pharmaceuticals’s EPS estimate?
Acurx Pharmaceuticals’s EPS estimate is -0.38.
How many shares outstanding does Acurx Pharmaceuticals have?
Acurx Pharmaceuticals has 4,297,738 shares outstanding.
What happened to Acurx Pharmaceuticals’s price movement after its last earnings report?
Acurx Pharmaceuticals reported an EPS of -$0.62 in its last earnings report, beating expectations of -$1.2. Following the earnings report the stock price went down -5.963%.
Which hedge fund is a major shareholder of Acurx Pharmaceuticals?
Currently, no hedge funds are holding shares in ACXP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Acurx Pharmaceuticals
Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostridium difficile infections. Additionally, Acurx is progressing with ACX-375C, an investigational therapeutic suitable for both oral and injectable administration. This compound is being developed to combat various gram-positive bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and penicillin-resistant Streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was established in 2017 and is headquartered in Staten Island, New York.
ACXP Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call conveyed materially positive clinical and IP progress: compelling Phase II efficacy with no observed recurrence among cured patients, initiation of an rCDI pilot, favorable FDA guidance that could reduce pivotal trial requirements, strengthened patent protection, supportive preclinical data, and recent financings that improved cash. Key negatives are the modest cash position relative to Phase III needs, small-scale early rCDI data requiring larger controlled trials, and remaining regulatory and design uncertainties. On balance, the positive clinical, regulatory and IP developments outweigh the operational and financing risks disclosed.View all ACXP earnings summariesACXP Stock 12 Month Forecast
Average Price Target
$17.00
▲(511.51% Upside)
Technical Analysis
Ibio
―
Windtree Therapeutics
―
BioRestorative Therapies
―
Lixte Biotechnology Holdings
―
Bolt Biotherapeutics
―
Ownership Overview
55.41%
Insiders
1.06% Mutual Funds
0.34% Other Institutional Investors
42.46% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---